Xilio Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Xilio Therapeutics, Inc. (XLO) reported Increase (Decrease) in Accounts Payable of -$419.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-12
- Xilio Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $1.26M, a 40.29% decline year-over-year.
- Xilio Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$1.68M.
- Xilio Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $428.00K, a 73.28% decline year-over-year.
- Xilio Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$1.80M.
- Xilio Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was $152.00K, a 90.04% decline from fiscal 2024.
- Xilio Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was $1.53M.
- Xilio Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$2.06M, a 525.36% decline from fiscal 2022.
- Xilio Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2022 was $485.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 3 month as first filed | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 6 month as first filed | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$419.00K 10-Q · filed 2026-08-12 | $9.00K derived: sum of 3 quarters · filed 2026-08-12 | -$1.79M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2026-03-31 | -$1.68M 10-Q · filed 2026-05-12 | -$1.25M derived: sum of 2 quarters · filed 2026-05-12 | -$3.05M derived: sum of 3 quarters · filed 2026-05-12 | -$938.00K derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-12-31 | $428.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$1.37M derived: sum of 2 quarters · filed 2026-03-23 | $742.00K derived: sum of 3 quarters · filed 2026-08-12 | $152.00K 10-K · filed 2026-03-23 | ||
| 2025-09-30 | -$1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $314.00K derived: sum of 2 quarters · filed 2026-08-12 | -$276.00K 10-Q · filed 2025-11-13 | $1.33M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-06-30 | $2.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.52M 10-Q · filed 2026-08-12 | $3.12M derived: sum of 3 quarters · filed 2026-08-12 | $2.84M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | -$590.00K 10-Q · filed 2026-05-12 | $1.01M derived: sum of 2 quarters · filed 2026-05-12 | $732.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.24M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.32M derived: sum of 2 quarters · filed 2026-03-23 | $1.83M derived: sum of 3 quarters · filed 2026-03-23 | $1.53M 10-K · filed 2026-03-23 | ||
| 2024-09-30 | -$280.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $229.00K derived: sum of 2 quarters · filed 2025-11-13 | -$76.00K 10-Q · filed 2025-11-13 | -$514.00K derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $509.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $204.00K 10-Q · filed 2025-08-14 | $205.00K 10-Q · filed 2024-08-08 | -$234.00K derived: sum of 3 quarters · filed 2025-08-14 | $308.00K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$305.00K 10-Q · filed 2025-05-08 | -$304.00K 10-Q · filed 2024-05-14 | -$743.00K derived: sum of 2 quarters · filed 2025-05-08 | -$201.00K derived: sum of 3 quarters · filed 2025-05-08 | -$1.01M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$438.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $104.00K derived: sum of 2 quarters · filed 2025-03-11 | -$705.00K derived: sum of 3 quarters · filed 2025-03-11 | -$2.06M 10-K · filed 2025-03-11 | ||
| 2023-09-30 | $542.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$267.00K derived: sum of 2 quarters · filed 2024-11-07 | -$1.63M 10-Q · filed 2024-11-07 | -$168.00K derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | -$809.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$2.17M 10-Q · filed 2024-08-08 | -$710.00K derived: sum of 3 quarters · filed 2024-08-08 | -$465.00K derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | -$1.36M 10-Q · filed 2024-05-14 | $99.00K derived: sum of 2 quarters · filed 2024-05-14 | $344.00K derived: sum of 3 quarters · filed 2024-05-14 | -$53.00K derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $1.70M derived: sum of 2 quarters · filed 2024-04-01 | $1.30M derived: sum of 3 quarters · filed 2024-04-01 | $485.00K 10-K · filed 2024-04-01 | ||
| 2022-09-30 | $245.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$152.00K derived: sum of 2 quarters · filed 2023-11-09 | -$972.00K 10-Q · filed 2023-11-09 | -$2.16M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | -$397.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$1.22M 10-Q · filed 2023-08-14 | -$2.41M derived: sum of 3 quarters · filed 2023-08-14 | -$5.96M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | -$820.00K 10-Q · filed 2023-05-09 | -$2.01M derived: sum of 2 quarters · filed 2023-05-09 | -$5.56M derived: sum of 3 quarters · filed 2023-05-09 | -$800.00K derived: sum of 4 quarters · filed 2023-05-09 | ||
| 2021-12-31 | -$1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$4.74M derived: sum of 2 quarters · filed 2023-03-02 | $20.00K derived: sum of 3 quarters · filed 2023-03-02 | -$2.82M 10-K · filed 2023-03-02 | ||
| 2021-09-30 | -$3.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.21M derived: sum of 2 quarters · filed 2022-11-09 | -$1.63M 10-Q · filed 2022-11-09 | $962.00K derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $4.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.92M 10-Q · filed 2022-08-09 | $4.51M derived: sum of 3 quarters · filed 2022-08-09 | |||
| 2021-03-31 | -$2.84M 10-Q · filed 2022-05-12 | -$250.00K derived: sum of 2 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $2.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $2.93M 10-K · filed 2022-03-01 | ||||
| 2020-09-30 | $338.00K 10-Q · filed 2021-12-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |